From an application perspective, the market taxonomy is cleaved into Children, Adults, and Seniors, each anchoring discrete volume and value pools. Children’s formulations (4–12 y) are constrained by EFSA/USDA upper tolerable limits, capping elemental iron at 10 mg; consequently, SKUs rely on higher ASP per gram and character-licensing to offset smaller pill-size, accounting for 22 % of 2023 global sales. The Adult cluster—driven by 18–45 y female vegans with heavy menstrual losses—represents 54 % of revenues, sustained by 25–35 mg high-bioavailability gummies bundled with vitamin C. Seniors (55 y+) generate the fastest CAGR (9.2 %) as veganism rises in the 60+ cohort; formulations here embed ferrous bisglycinate chelate plus vitamin B12 to address atrophic gastritis-induced malabsorption, commanding a 20 % higher AUV than mainstream adult SKUs.